Delayed
Toronto S.E.
14:37:12 28/06/2024 BST
|
5-day change
|
1st Jan Change
|
0.06
CAD
|
0.00%
|
|
-7.69%
|
-76.00%
|
Fiscal Period: November |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
426.9
|
110.1
|
76.13
|
40.24
|
28.37
|
5.577
|
Enterprise Value (EV)
1 |
348.8
|
72.24
|
66.23
|
25.41
|
24.36
|
5.326
|
P/E ratio
|
-10.8
x
|
-1.72
x
|
-2.9
x
|
-1.64
x
|
-1.75
x
|
-0.35
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
22.4
x
|
6.74
x
|
3.03
x
|
1.76
x
|
1.29
x
|
0.26
x
|
EV / Revenue
|
18.3
x
|
4.42
x
|
2.64
x
|
1.11
x
|
1.1
x
|
0.25
x
|
EV / EBITDA
|
-11.5
x
|
-2.79
x
|
-2.65
x
|
-1.06
x
|
-1.75
x
|
-0.46
x
|
EV / FCF
|
-
|
-5,101,347
x
|
-2,997,772
x
|
-3,155,232
x
|
-2,326,193
x
|
-6,930,276
x
|
FCF Yield
|
-
|
-0%
|
-0%
|
-0%
|
-0%
|
-0%
|
Price to Book
|
3.92
x
|
1.97
x
|
2.6
x
|
1.55
x
|
2.13
x
|
1.61
x
|
Nbr of stocks (in thousands)
|
15,358
|
16,188
|
16,198
|
20,118
|
21,822
|
27,885
|
Reference price
2 |
27.80
|
6.800
|
4.700
|
2.000
|
1.300
|
0.2000
|
Announcement Date
|
31/05/19
|
30/04/20
|
30/03/21
|
25/03/22
|
30/03/23
|
02/04/24
|
Fiscal Period: November |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
19.04
|
16.34
|
25.1
|
22.82
|
22.07
|
21.66
|
EBITDA
1 |
-30.45
|
-25.89
|
-24.99
|
-24.02
|
-13.93
|
-11.51
|
EBIT
1 |
-31.76
|
-27.63
|
-26.2
|
-25.33
|
-15.12
|
-12.56
|
Operating Margin
|
-166.82%
|
-169.08%
|
-104.36%
|
-110.99%
|
-68.52%
|
-57.97%
|
Earnings before Tax (EBT)
1 |
-33.63
|
-63.6
|
-26.18
|
-23.64
|
-18.92
|
-14.12
|
Net income
1 |
-33.28
|
-63.17
|
-26.25
|
-23.8
|
-15.44
|
-14.13
|
Net margin
|
-174.81%
|
-386.57%
|
-104.56%
|
-104.3%
|
-69.94%
|
-65.22%
|
EPS
2 |
-2.569
|
-3.946
|
-1.621
|
-1.220
|
-0.7414
|
-0.5791
|
Free Cash Flow
|
-
|
-14.16
|
-22.09
|
-8.054
|
-10.47
|
-0.7685
|
FCF margin
|
-
|
-86.67%
|
-88.01%
|
-35.3%
|
-47.45%
|
-3.55%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
31/05/19
|
30/04/20
|
30/03/21
|
25/03/22
|
30/03/23
|
02/04/24
|
Fiscal Period: November |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
78.2
|
37.8
|
9.9
|
14.8
|
4.01
|
0.25
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-14.2
|
-22.1
|
-8.05
|
-10.5
|
-0.77
|
ROE (net income / shareholders' equity)
|
-
|
-76.5%
|
-62.4%
|
-86.5%
|
-94.8%
|
-168%
|
ROA (Net income/ Total Assets)
|
-
|
-18.7%
|
-30.6%
|
-41%
|
-32.2%
|
-46.1%
|
Assets
1 |
-
|
337.8
|
85.72
|
58.03
|
47.88
|
30.66
|
Book Value Per Share
2 |
7.100
|
3.450
|
1.810
|
1.290
|
0.6100
|
0.1200
|
Cash Flow per Share
2 |
5.060
|
2.340
|
0.6300
|
0.6300
|
0.1700
|
0.0500
|
Capex
1 |
1.15
|
0.53
|
3.44
|
0.37
|
0.69
|
0.33
|
Capex / Sales
|
6.05%
|
3.22%
|
13.69%
|
1.61%
|
3.14%
|
1.53%
|
Announcement Date
|
31/05/19
|
30/04/20
|
30/03/21
|
25/03/22
|
30/03/23
|
02/04/24
|
|
1st Jan change
|
Capi.
|
---|
| -76.00% | 1.33M | | +26.34% | 261M | | -3.09% | 211M | | +25.00% | 167M | | +40.89% | 130M | | +300.00% | 121M | | -54.07% | 103M | | -28.57% | 96.6M | | +71.19% | 96.17M | | -23.08% | 66.82M |
Medical Farming
|